Caplin Point rises after its subsidiary gets USFDA nod for generic version of Bloxiverz injection
Caplin Point rises after its subsidiary gets USFDA nod for generic version of Bloxiverz injection

Caplin Point rises after its subsidiary gets USFDA nod for generic version of Bloxiverz injection

Anthony Fernandes Article rating: 4.0

On Thursday, Caplin Point Laboratories announced that its subsidiary, Caplin Steriles Limited has been granted final approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate injection.   

Best performing pension fund managers
Best performing pension fund managers

Best performing pension fund managers

Henil Shah Article rating: 3.5

NPS is one such investment that everyone must have, irrespective of their income. In this article, we would be revealing the best pension fund managers. So, keep reading.

This low P/E stock is trading at lifetime high
This low P/E stock is trading at lifetime high

This low P/E stock is trading at lifetime high

Geyatee Deshpande Article rating: 3.8

Usually, low P/E stocks are considered attractive for investments. However, not all low P/E stocks turn out to be multibaggers. Titan Biotech is one such stock, which is trading at low P/E and is turning out to be a classic multibagger. 

Five stocks witnessing long built-up
Five stocks witnessing long built-up

Five stocks witnessing long built-up

Ganesh Pawar Article rating: 4.6

The market opened in red on April 22, 2021, overall volumes in futures & options currently stand at 4,56,59,667 contracts with a turnover of Rs. 41,71,483.21 crore.

Five stocks witnessing short built-up
Five stocks witnessing short built-up

Five stocks witnessing short built-up

Ganesh Pawar Article rating: 4.0

The market opened in red on April 22, 2021, overall volumes in futures & options currently stand at 4,56,59,667 contracts with a turnover of Rs. 41,71,483.21 crore.

Upper circuit stock: Wanbury with low P/E, now on verge of breakout
Upper circuit stock: Wanbury with low P/E, now on verge of breakout

Upper circuit stock: Wanbury with low P/E, now on verge of breakout

Shreya Chaware Article rating: 3.4

Several pharma stocks are rallying and Wanbury is just another lesser-known name that is attracting investors. According to BSE website, the company is trading at a P/E of 4, with a market cap (free float) of Rs 107 crore.  

RSS
First23692370237123722374237623772378Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR